ScreenerHero

MRKR Marker Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · markertherapeutics.com
0.9500USD-8.65%Mkt Cap: 15.84M $P/E: —

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United Stat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap15.84M USD
Enterprise Value5.51M USD
Revenue (TTM)3.55M USD
Gross Profit-5.26M USD
Net Income (TTM)-12.16M USD
Revenue/Share0.19 USD
Last Price0.9500 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA—
EV/Revenue1.55
P/S4.75
P/B1.38
EPS (TTM)-0.42
EPS (Forward)-0.53
52W Range
0.84007% of range2.460
52W High2.460 USD
52W Low0.8400 USD
Profitability
Gross Margin-148.28%
Oper. Margin-267.95%
EBITDA Margin0.00%
Profit Margin-245.51%
ROE-72.42%
ROA-63.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.01M USD
CapEx (TTM)—
FCF Margin-175.57%
FCF Yield-39.31%
Net Debt-11.33M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio6.03
Quick Ratio5.35
Book Value/Sh0.73 USD
Cash/Share0.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 16, 2016
Splits
Last Split1:10
Split DateJan 27, 2023
Analyst Consensus
Rating—
Target (Mean)7.867 USD
Upside (mean)+728.1%
Target Range5.600 USD – 10.00 USD
5.600+728.1% to mean10.00
# Analysts3
Ownership
Shares Out.16.67M
Float13.74M
Insiders5.49%
Institutions23.80%
Short Interest
Short Ratio2.7d
Short % Float1.68%
Short % Out.1.36%
Shares Short226.62K
Short (prev mo.)200.21K
Technical
SMA 501.200 (-20.8%)
SMA 2001.425 (-33.3%)
Beta1.53
S&P 52W Chg16.45%
Avg Vol (30d)84.74K
Avg Vol (10d)90.81K
Technical Indicators
RSI (14)31.5
MACD-0.0617
MACD Signal-0.0458
MACD Hist.-0.0159
BB Upper1.285 USD
BB Middle1.125 USD
BB Lower0.9652 USD
BB Width28.45%
ATR (14)0.0822 USD
Vol Ratio (20d)1.29x